Dubai’s Arab Health: Leading New Medical Advances
Join us at the Arab Health 2024 conference, set in the vibrant city of Dubai, from January 29 to...
FDA Nods Merck’s Keytruda for Stage III-IVA Cervical Cancer
Merck announced that the FDA has approved KEYTRUDA, their anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for treating patients...
Innovative DCT Leap: Bayer’s New OCEANIC Study
The Vanguard of Decentralized Clinical Trials: Bayer’s OCEANIC Study The Medidata NEXT conference spotlighted the groundbreaking OCEANIC study by...
Revolutionary Digital Twins: The Future of Clinical Trials
In this interview with Gian Carlo (GC) Ochoa, a leading figure in digital twins technology for clinical trials, we...
Cytonics CYT-108: A Unique Approach to OA Treatment
In this interview, we spoke with Joey Bose, President & CEO of Cytonics, diving into the intricacies of their...
Pfizer Tivdak SLA Accepted by FDA for Priority Cervical Cancer Review
Genmab A/S and Pfizer Inc. announced the FDA’s acceptance of the supplemental Biologics License Application (sBLA) to potentially convert...
ICON Sets Financial Forecast for 2024 Full Year
ICON plc, a global clinical research organization, has projected financial targets for the year ending December 31, 2024. The...
FDA NIH & DARPA Government Agencies Lead New DCT Initiatives
In today’s discussion, we’re joined by Craig Lipset, Co-Chair of the Decentralized Trials & Research Alliance (DTRA), who shares...
Master Protocols: FDA New Flexible Approach in Cancer Trials
Master Protocols (MPs) mark a significant evolution in the realm of clinical research, especially notable in oncology. These protocols,...
Innovative Merck-Inspirna Deal: New Hope in Cancer Battle
Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc., New York, for the development of...